Binding of Psychotropic Drugs to Isolated Alpha-acid Glycoprotein
Overview
Pharmacology
Authors
Affiliations
Alpha1-acid glycoprotein (alpha1-AG) was purified from human sera, and its binding properties with respect to psychotropic drugs were examined by equilibrium dialysis methods in order to clarify the specificity of binding. Radioactive imipramine, a tricyclic antidepressant, was used as the primary ligand. Other drugs, representative of different classes, were tested as potential inhibitors of the alpha1-AG-imipramine binding. The K(a) for imipramine was 2.8 x 10(5) (+/- 0.8) M(-10 (mean +/- S.D.). Chlorpromazine, fluphenazine, thioridazine, loxapine and thiothixene, which are antipsychotic drugs, were competitive inhibitors of imipramine binding, and their K(a) values were in the same range. Propranolol, haloperidol and diazepam were also competitive inhibitors but their affinities were lower. Molindone, an indolic antipsychotic, when tested at the same concentrations as the other drugs, did not affect imipramine binding. Trihexyphenidyl, an anti-Parkinson drug, was a potent but noncompetitive inhibitor. These data identify the antidepressant and major tranquilizer drugs that exhibit high affinity for alpha1-AG and indicate that alpha1-AG may account for 40 per cent of total imipramine bound in serum. Since in psychiatric clinical practice two drugs are frequently administered together, possible competitive effects are discussed as well as the potential role of alpha1-AG in psychiatric illness.
Protein binding of anthraquinone glycosides, with special reference to adriamycin.
Eksborg S, Ehrsson H, Ekqvist B Cancer Chemother Pharmacol. 1982; 10(1):7-10.
PMID: 7160048 DOI: 10.1007/BF00257228.
The binding of ketamine to plasma proteins: emphasis on human plasma.
Dayton P, STILLER R, Cook D, Perel J Eur J Clin Pharmacol. 1983; 24(6):825-31.
PMID: 6884418 DOI: 10.1007/BF00607095.
Muller W, Stillbauer A Naunyn Schmiedebergs Arch Pharmacol. 1983; 322(2):170-3.
PMID: 6866130 DOI: 10.1007/BF00512392.
Meijer D, Scholtens H, HARDONK M Pharm Weekbl Sci. 1982; 4(3):57-70.
PMID: 6180375 DOI: 10.1007/BF01962246.
Tinguely D, Baumann P, Conti M, Schopf J Eur J Clin Pharmacol. 1985; 27(6):661-6.
PMID: 3987771 DOI: 10.1007/BF00547045.